Clinical Research Directory

Inclusion Criteria: 1. Enrolled in and eligible (based on screening procedures - Visit 1) for the main EGCG Phase 1 study, "Dose ranging study of oral epigallocatechin-3-gallate (EGCG) given daily for 12 weeks to patients with Idiopathic Pulmonary Fibrosis (IPF) evaluating safety, PK interactions with standard of care drugs, and biomarkers of drug effect 2. Signed informed consent Exclusion Criteria: 1. Pregnant or breastfeeding (a negative quantitative serum human chorionic gonadotropin (hCG) pregnancy test is required for females having child-bearing potential before the participant can participate)\* 2. Research-related radiation exposure exceeds 50 millisievert (mSv) in the prior 12 months 3. Determined by the investigator to be clinically unsuitable for the study Additional exclusion criteria for participants undergoing PET-MRI: 1. Electrical implants such as cardiac pacemaker, defibrillator, or perfusion pump 2. Metallic or electric implants contraindicated for magnetic resonance-PET (MR-PET) scanning 3. Claustrophobic reactions 4. Estimated glomerular filtration rate (eGFR) of less than 30 mL/min/1.73 m2 within the prior 30 days 5. Known allergy to gadolinium * Women of childbearing potential (WCBP) are defined as a sexually mature woman not surgically sterilized or not post-menopausal for at least 24 consecutive months if \< 55 years or 12 months if ≥ 55 years.